API | malarone

malarone Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Atovaquone/proguanil, sold under the brand name Malarone among others, is a fixed-dose combination medication used to treat and prevent malaria, including chloroquine-resistant malaria. It contains atovaquone and proguanil. It is not recommended for severe or complicated malaria. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: CC1(C)N=C(N)N=C(N)N1c2ccc(Cl)cc2
InChIKey: QMNFFXRFOJIOKZ-UHFFFAOYSA-N
Mol. Mass: 251.72
ALogP: 1.53 Partition coefficient
ChEMBL Molecule:
cycloguanil

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

malarone

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Biological Availability (Phase 1)

Exercise (Phase 4)

Malaria (Phase 4)

Malaria, Falciparum (Phase 1)

Pharmacokinetics (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue